Search results
Amgen plows ahead with costly, highly toxic cancer dosing despite FDA challenge
Boston Herald· 16 hours agoWhen doctors began using the drug sotorasib in 2021 with high expectations for its innovative...
Hospital is first in WNY to offer noninvasive prostate cancer therapy
WGRZ-TV Buffalo· 24 hours agoPerformed noninvasively in the outpatient setting under general anesthesia, HIFU uses focal therapy...
Fusion Pharmaceuticals doses first subject in prostate cancer trial
Clinical Trials Arena via Yahoo Finance· 1 day agoThe open-label, randomised, multicentre AlphaBreak trial aims to determine the safety and...
US County-Level Study Shows Benefits of PSA Screening
Medscape· 1 day agoA recent analysis found that US counties with higher rates of PSA screening had lower rates of...
New Study Demonstrates Avenda Health's Unfold AI to Better Predict Focal Therapy Success by 77%...
FOX 59 Indianapolis· 3 days agoAvenda Health, an AI healthcare company creating the future of personalized prostate cancer care,...
No PSA Recurrence at 24 Months With Apalutamide Plus ADT After Radical Prostatectomy
MedPage Today· 6 days agoMore than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed...
New Drugs Won’t Help If They Can’t Reach Patients. My Family Learned the Hard Way.
Barrons.com· 4 days agoChristine Schuster spent her life in healthcare. That wasn’t enough when her husband couldn’t get...
...Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across...
Digital Journal· 5 days ago“The TACT 5-year clinical trial data, along with multiple real-world reports on the safety, efficacy and durability of TULSA from ...
Opko Health (OPK) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 3 days agoFDA concluded that the 4Kscore Test had the appropriate sensitivity of 96.9% and negative predictive value of 95.9% to contribute to an overall...
Abbott’s Jennifer Jones-McMeans on treating PAD below the knee
MedTech Dive via Yahoo Finance· 2 days agoJennifer Jones-McMeans, a leader in Abbott’s vascular unit, discussed the company’s newly approved...